“It was mostly mild or asymptomatic despite being detected on brain scans - but 1.6% developed dangerous brain swelling, with two deaths directly attributed to it and a third volunteer dying after such a case.”
Eli Lilly’s donanemab slowed Alzheimer’s by about 29% overall. The 35% in the headline comes from the patients researchers picked as more likely to respond. Two trial deaths were directly attributed to brain swelling, and a third followed one. Slower decline is real progress, and the headline rounds up.